Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
120.55
+1.01 (0.84%)
After Hours: 120.55 0.00 (0.00%)
Apr 25, 5:57PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 119.47 - 122.07
52 week 109.12 - 159.93
Open 120.02
Vol / Avg. 0.00/1.77M
Mkt cap 27.77B
P/E 68.50
Div/yield     -
EPS 1.76
Shares 225.15M
Beta 1.33
Inst. own 100%
May 10, 2017
Alexion Pharmaceuticals Inc Annual Shareholders Meeting - 5:30PM EDT - Add to calendar
Apr 27, 2017
Q1 2017 Alexion Pharmaceuticals Inc Earnings Call - 10:00AM EDT - Add to calendar
Apr 27, 2017
Q1 2017 Alexion Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Mar 7, 2017
Alexion Pharmaceuticals Inc at Raymond James Institutional Investors Conference
Mar 6, 2017
Alexion Pharmaceuticals Inc at Cowen Health Care Conference - Webcast
Feb 16, 2017
Q4 2016 Alexion Pharmaceuticals Inc Earnings Call - Webcast
Feb 16, 2017
Q4 2016 Alexion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 11.13% 12.94%
Operating margin 15.30% 21.63%
EBITD margin - 38.55%
Return on average assets 2.79% 3.03%
Return on average equity 4.31% 4.71%
Employees 3,121 -
CDP Score - -

Address

100 College St
NEW HAVEN, CT 06510-3210
United States - Map
+1-203-2722596 (Phone)
+1-203-2718198 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
David John Anderson Chief Financial Officer
Age: 67
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 60
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 50
Bio & Compensation  - Reuters
Carsten Thiel Ph.D. Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 52
Bio & Compensation  - Reuters
Heidi L. Wagner J.D. Senior Vice President - Global Governmental Affairs
Age: 52
Bio & Compensation  - Reuters